These results strongly suggest that the deficiency of CX3CR1 targeted on the CX3CR1/CX3CL1 axis may impair the CAR-T therapeutic effect by inducing immune cell infiltration and CAR-T cell homing in DLBCL. Here, CX3CL1 is linked to diffuse large B-cell lymphoma.